# A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

> **NCT00782093** · PHASE1 · COMPLETED · sponsor: **Ophthotech Corporation** · enrollment: 63 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** volociximab

## Key facts

- **NCT ID:** NCT00782093
- **Lead sponsor:** Ophthotech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782093, "A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00782093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*